|
|
 |
|
Viewing report
|
|
|
|
Epidemiology: Hepatitis B in China
Datamonitor, March 2011, Pages: 33
Even with the projected overall decrease during the forecast period, the prevalence of hepatitis B will continue to remain at the intermediate endemicity level. China will have an estimated 63.06 million prevalent cases of hepatitis B in 2020.
Scope of the report:
- Gain insight into market potential, including a robust, 10-year epidemiology forecast of hepatitis B prevalent cases.
- Understand the key epidemiologic risk factors associated with hepatitis B in China.
Highlights:
- It is estimated that the prevalence of hepatitis B in China is highest among adults aged 40–49 years and also 50–59 years; both age groups are projected to have an increase in the number of prevalent cases during the forecast period, according to forecasts.
- The increase in the two oldest groups (40–49 and 50–59) is directly related to the projected population growth in these age groups. The two age groups will remain unaffected by the change in vaccination policy during the forecast period.
Reasons to buy:
- What are the most robust sources for hepatitis B prevalence data?
- How will patient the population change over the next decade in China?
- How do changes in population structure and risk factors affect the trend in prevalent hepatitis B cases?
|
|
|
|
